Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
Monte Rosa Therapeutics (NASDAQ: GLUE), a biotechnology firm focused on developing innovative molecular glue degrader-based therapies, has announced its participation in several upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Monte Rosa Therapeutics (NASDAQ: GLUE), a biotechnology firm focused on developing innovative molecular glue degrader-based therapies, has announced its participation in several upcoming investor conferences. These include the Credit Suisse 31st Annual Healthcare Conference from November 7-10, the Jefferies 13th Annual London Healthcare Conference from November 15-17, and the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1. Archived webcasts will be available on the company's investor site.
Monte Rosa leverages its proprietary QuEEN™ platform for protein degradation in drug discovery.
Details
News Market Reaction – GLUE
The recorded move for GLUE in the trading session of this news was -1.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company will participate in the following upcoming investor conferences:
- Credit Suisse 31st Annual Healthcare Conference (Nov. 7-10)
- Jefferies 13th Annual London Healthcare Conference (Nov. 15-17)
- Piper Sandler 34th Annual Healthcare Conference (Nov. 29-Dec. 1)
Where applicable, archived webcasts can be accessed via the “Events & Presentations” section of the company’s investor site at https://ir.monterosatx.com/.
About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader (MGD) medicines. These medicines are designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), that enables it to rapidly identify protein targets and MGD drug candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection, and computational chemistry capabilities to predict and obtain protein degradation profiles. For more information, visit www.monterosatx.com.
Contacts:
Investors
Michael Morabito, Solebury Trout
ir@monterosatx.com
Media
Dan Budwick, 1AB
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.